Jiangsu Tairui Shengnuo Biopharmaceutical Technology

Tairui Shengnuo is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative small molecule therapeutics for metabolic diseases. The company's primary focus is on multi-agonist treatments targeting the GLP-1, GIP, and glucagon receptors to address conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Their lead candidate, TRS005, is an orally available small molecule triple agonist designed to provide superior efficacy and convenience compared to existing injectable peptide therapies. Tairui Shengnuo aims to leverage its expertise in medicinal chemistry to create next-generation metabolic treatments with improved safety and patient compliance profiles.